If it is speculated according to the law of the past nine batches of national procurement, the tenth batch of national centralized procurement will most likely be launched around May this year.
According to statistics, there are currently 101 varieties that have not been evaluated by the national procurement of 5 or more (original research + imitation), which initially meet the basic conditions of national procurement. Details are shown in the table below
A list of more than 5 varieties has been evaluated
*It is manually organized, if there are any errors, please refer to the actual data01 Right Rezosen, Esmolor or "Inevitable" Tenth Batch
Levonororgestrel may be the third time to flow the standard.
The sales scale of esmolol national hospitals
However, referring to the experience of carbetocin that was transferred in the past in the ninth batch of successful national collection, we know that dexrezosen and esmolol may not escape the tenth batch of national collection.
Different from their fate, levonorgestrel may set a record for the third national procurement in the tenth batch of national collection, which is mainly determined by the difference in use scenarios. As a family planning product, levonorgestrel has a very small demand in the hospital. In the eighth batch of centralized procurement, the centralized procurement amount of levonorgestrel is only about 2 million yuan, which is the variety with the smallest purchase amount. Even in the ninth batch of centralized procurement, the medical insurance bureau increased its two specifications by 2 yuan and 3 yuan respectively, and only made the centralized procurement amount reach about 3.8 million yuan, compared with levonorgestrel's annual sales of about 2 billion yuan in the retail channel market, it is not surprising that the bid failed.
Levonoorgestrel National Retail Channel Market (2020-2022).
02 Some varieties have been collected locally.
Pharmaceutical companies took the initiative to choose to cut prices before the 10th batch of national procurement.
Due to the current national linkage and four same governance, the lowest price of centralized procurement in some places may become the most popular reference value in other provinces.
For example, in the previous centralized procurement of drugs in Fujian Province, Zhengda Tianqing's aprepitant capsule was selected at a price of 5767 yuan, a decrease of 61%; Jiangsu Wangao resorcinol injection, with 218 yuan exclusive selection, a decrease of 92%; Ambroterol oral solution, Hebei Chuangjian 995 yuan was selected, a decrease of 83%; Zhejiang Zhida's doxorubicin hydrochloride liposome was selected exclusively for 1580 yuan, a decrease of 64%.
These 4 varieties are in the above list of more than 5 varieties, because the national procurement conditions of these varieties have matured, sooner or later they will have to reduce the price, so it is reasonable for some pharmaceutical companies to choose to reduce the price in advance.
03 Patent protection in the field of chronic disease medication
There are not many large varieties that can be collected
In fact, in the past nine national drug procurements, they have basically covered the commonly used varieties in the field of chronic diseases such as hypertension, heart disease, and diabetes.
At present, most of the chronic disease drugs that have not been centrally procured are drugs within the patent protection period, although the number of enterprises that have passed the evaluation is enough, but the tenth batch of national centralized procurement will obviously not be included. For example, sacubitril-valsartan sodium, tolvaptan tablets, dapagliflozin, alogliptin benzoate, sitagliptin tablets, sitagliptin metformin and other drugs are still in the patent protection period. Among them, the fastest expiration of the patent is sitagliptin, as a large variety with annual sales of more than 2 billion in China, its pharmaceutical active ingredient patent will expire in June this year, and it is likely that it will not catch up with the tenth batch of national procurement.
In addition, it is worth noting that after the core patent of linagliptin expired in August 2023, the East Sunshine generic drug linagliptin tablets, which were originally withdrawn due to infringement, were restored to the network qualification by Guangdong, Shanghai and other places, but the protection period of many patents of Boehringer Ingelheim's linagliptin can be until 2030, and whether it can participate in the tenth batch of national procurement also depends on whether there are obstacles in patents.
*: Shanghai Pharmaceutical Centralized Bidding and Procurement Affairs Management Office.
Also limited by patents, the listing of generic drug companies with dapagliflozin tablets has been blocked. Among them, the compound patent has expired in May 2023, and the remaining composition and use patents are still valid, and the protection period is June 21, 2027 at the earliest, and April 1, 2041 at the latest. **New Kang Circle